The trial, conducted at UCSF’s TrPR Lab, is first to use naturally derived psychedelic drug candidates and first to directly administer psilocin, the active form of psilocybin VANCOUVER, BC, July 7, 2022 /CNW/ – Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament”), a clinical-stage natural psychedelic drug development company, today announced the beginning of dosing in the first…


Previous articlePT335 – Christopher Dawson & Andrew Galloway – Modernizing Traditional Plant Medicine With Neuroscience and Luxury
Next articlePsychedelic Research Bulletin: June 2022